JP7399109B2 - 縮合チオフェン誘導体及びそれらの使用 - Google Patents
縮合チオフェン誘導体及びそれらの使用 Download PDFInfo
- Publication number
- JP7399109B2 JP7399109B2 JP2020565533A JP2020565533A JP7399109B2 JP 7399109 B2 JP7399109 B2 JP 7399109B2 JP 2020565533 A JP2020565533 A JP 2020565533A JP 2020565533 A JP2020565533 A JP 2020565533A JP 7399109 B2 JP7399109 B2 JP 7399109B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- alkyloxy
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305133.3 | 2018-02-08 | ||
| EP18305133 | 2018-02-08 | ||
| PCT/EP2019/053074 WO2019154950A1 (en) | 2018-02-08 | 2019-02-08 | Fused thiophene derivatives and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514384A JP2021514384A (ja) | 2021-06-10 |
| JP2021514384A5 JP2021514384A5 (cg-RX-API-DMAC7.html) | 2022-02-15 |
| JP7399109B2 true JP7399109B2 (ja) | 2023-12-15 |
Family
ID=61283123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565533A Active JP7399109B2 (ja) | 2018-02-08 | 2019-02-08 | 縮合チオフェン誘導体及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11492347B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3749658A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7399109B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200141436A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111954668A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019216793B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020015907A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3087829A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202091889A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL275905A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020007918A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019154949A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| MX2020007918A (es) | 2018-02-08 | 2020-12-03 | Enyo Pharma | Derivados fusionados de tiofeno y sus usos. |
| EA202091897A1 (ru) | 2018-02-08 | 2020-10-27 | Энио Фарма | Неконденсированные производные тиофена и их применение |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| WO2020210582A1 (en) * | 2019-04-11 | 2020-10-15 | University Of The Sciences | Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor |
| RU2756587C9 (ru) * | 2021-02-12 | 2021-10-12 | Акционерное общество "Отисифарм" | Производные 2-ацетамидо-6-гидрокси-бензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью |
| JP7849841B2 (ja) | 2021-02-16 | 2026-04-22 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | リソソーム関連膜タンパク質標的化化合物及びその使用 |
| TWI815475B (zh) * | 2021-05-27 | 2023-09-11 | 財團法人國家衛生研究院 | Cdgsh鐵硫結構域2活化劑及其用途 |
| CN113264917B (zh) * | 2021-05-28 | 2022-07-01 | 华南理工大学 | 一种抗乙肝病毒化合物及其制备方法和应用 |
| CN113501807A (zh) * | 2021-06-10 | 2021-10-15 | 重庆科技学院 | 四氢苯并噻吩类化合物及药物组合物的制备方法和用途 |
| WO2023114761A2 (en) * | 2021-12-14 | 2023-06-22 | West Virginia University Board of Governors on behalf of West Virginia University | Targeting ero1 alpha with aurone derivatives |
| CN114891013A (zh) * | 2022-05-06 | 2022-08-12 | 南方科技大学 | 三尖杉碱类化合物的衍生物及其制备方法、药物组合物和用途 |
| CN117004526A (zh) * | 2023-08-04 | 2023-11-07 | 浙江工业大学 | 奥巴涅斯分枝杆菌wml及其在降解有机污染物中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171603A1 (en) | 2001-05-18 | 2004-09-02 | Janos Pato | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor |
| WO2005023818A2 (en) | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| JP2008517061A (ja) | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| JP2014169257A (ja) | 2013-03-05 | 2014-09-18 | Kyowa Hakko Kirin Co Ltd | 縮環チオフェン誘導体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6339198A (en) * | 1997-02-26 | 1998-09-18 | Ciblex Corporation | Inhibitors of leaderless protein export |
| WO2006093518A2 (en) | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
| WO2009026172A2 (en) | 2007-08-17 | 2009-02-26 | The Regents Of The University Of California | New approach for designing diabetes drugs |
| US20110015239A1 (en) | 2007-12-14 | 2011-01-20 | The Regents Of The University Of California | Inhibitors of calcium-activated chloride channels |
| WO2011097607A1 (en) * | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| US8765803B1 (en) | 2011-03-02 | 2014-07-01 | Stc.Unm | Rab7 GTPase inhibitors and related methods of treatment |
| WO2012148889A1 (en) | 2011-04-28 | 2012-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of human apurinic/apyrimidinic endonuclease 1 |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| US10647725B2 (en) | 2016-04-21 | 2020-05-12 | The University Of Toledo | Anti-infective 2-aminothiophenes |
| KR20190098204A (ko) | 2016-12-29 | 2019-08-21 | 엔요 파마 | 항바이러스제로서의 티오펜 유도체 |
| EA202091897A1 (ru) | 2018-02-08 | 2020-10-27 | Энио Фарма | Неконденсированные производные тиофена и их применение |
| MX2020007918A (es) | 2018-02-08 | 2020-12-03 | Enyo Pharma | Derivados fusionados de tiofeno y sus usos. |
| EP3749292A1 (en) | 2018-02-08 | 2020-12-16 | ENYO Pharma | Use of modulators of neet proteins for the treatment of infection |
-
2019
- 2019-02-08 MX MX2020007918A patent/MX2020007918A/es unknown
- 2019-02-08 US US16/967,746 patent/US11492347B2/en active Active
- 2019-02-08 CA CA3087829A patent/CA3087829A1/en active Pending
- 2019-02-08 EP EP19703105.7A patent/EP3749658A1/en not_active Withdrawn
- 2019-02-08 EP EP19703106.5A patent/EP3749659A1/en not_active Withdrawn
- 2019-02-08 AU AU2019216793A patent/AU2019216793B2/en not_active Ceased
- 2019-02-08 US US16/967,751 patent/US11603368B2/en active Active
- 2019-02-08 BR BR112020015907-7A patent/BR112020015907A2/pt not_active Application Discontinuation
- 2019-02-08 EA EA202091889A patent/EA202091889A1/ru unknown
- 2019-02-08 JP JP2020565533A patent/JP7399109B2/ja active Active
- 2019-02-08 WO PCT/EP2019/053072 patent/WO2019154949A1/en not_active Ceased
- 2019-02-08 CN CN201980012508.4A patent/CN111954668A/zh active Pending
- 2019-02-08 WO PCT/EP2019/053074 patent/WO2019154950A1/en not_active Ceased
- 2019-02-08 KR KR1020207023774A patent/KR20200141436A/ko not_active Ceased
-
2020
- 2020-07-07 IL IL275905A patent/IL275905A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171603A1 (en) | 2001-05-18 | 2004-09-02 | Janos Pato | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor |
| WO2005023818A2 (en) | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| JP2008517061A (ja) | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| JP2014169257A (ja) | 2013-03-05 | 2014-09-18 | Kyowa Hakko Kirin Co Ltd | 縮環チオフェン誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| PINKERTON; ET AL,SYNTHESIS AND SAR OF THIOPHENE CONTAINING KINESIN SPINDLE PROTEIN (KSP) INHIBITORS,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,2007年07月,VOL:17, NR:13,,PAGE(S):3562 - 3569,http://dx.doi.org/10.1016/j.bmcl.2007.04.076 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3749659A1 (en) | 2020-12-16 |
| WO2019154949A1 (en) | 2019-08-15 |
| IL275905A (en) | 2020-08-31 |
| US20200369682A1 (en) | 2020-11-26 |
| AU2019216793A1 (en) | 2020-08-06 |
| EP3749658A1 (en) | 2020-12-16 |
| MX2020007918A (es) | 2020-12-03 |
| CA3087829A1 (en) | 2019-08-15 |
| KR20200141436A (ko) | 2020-12-18 |
| US11492347B2 (en) | 2022-11-08 |
| WO2019154950A1 (en) | 2019-08-15 |
| CN111954668A (zh) | 2020-11-17 |
| US11603368B2 (en) | 2023-03-14 |
| BR112020015907A2 (pt) | 2020-12-15 |
| EA202091889A1 (ru) | 2020-10-29 |
| JP2021514384A (ja) | 2021-06-10 |
| US20200361924A1 (en) | 2020-11-19 |
| AU2019216793B2 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7399110B2 (ja) | 非縮合チオフェン誘導体及びそれらの使用 | |
| JP2021514384A (ja) | 縮合チオフェン誘導体及びそれらの使用 | |
| KR102286860B1 (ko) | 피리다지논 화합물 및 이의 용도 | |
| CN110114349B (zh) | 作为抗病毒剂的噻吩衍生物 | |
| CN112312904A (zh) | 螺环化合物 | |
| WO2017104691A1 (ja) | キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬 | |
| TW201702245A (zh) | 經取代之多環性吡啶酮衍生物及其前體藥物 | |
| JP2022511819A (ja) | ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法 | |
| JPH05202045A (ja) | 肝炎の処置に有用な1,3−オキサチオラン | |
| JP5539978B2 (ja) | チアゾピリミジノンおよびその使用 | |
| JP6619796B2 (ja) | Mif阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230814 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7399109 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |